• Abstract
• Full-Text PDF [311 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Lampertico, P
• Aghemo, A
• Viganò, M
• Colombo, M
• [+] on Google Scholar
• Lampertico, P
• Aghemo, A
• Viganò, M
• Colombo, M
• [+] on PubMed
• Lampertico, P
• Aghemo, A
• Viganò, M
• Colombo, M

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Viruses 2009, 1(3), 484-509; doi:10.3390/v1030484

Review

HBV and HCV Therapy

Pietro Lampertico* , Alessio Aghemo, Mauro Viganò and Massimo Colombo

“A.M. Migliavacca” Center for Liver Disease, First Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università di Milano, Via F. Sforza 35, 20122 Milan, Italy

* Author to whom correspondence should be addressed.

Received: 13 August 2009; in revised form: 8 October 2009 / Accepted: 19 October 2009 / Published: 22 October 2009

(This article belongs to the Special Issue Hepatitis Viruses)

Download PDF Full-Text [311 KB, uploaded 22 October 2009 14:37 CEST]

Abstract: One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.

Keywords: HBV DNA; nucleos(t)ide analogues; Peg-IFN; resistance; HCV RNA; Ribavirin; SVR

Article Statistics

Cite This Article